Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

31 evidence topics · 33 sources

Summary: lorundrostat and the add-on options for uncontrolled hypertension
  • Approved add-on drugs with a labeled hypertension indication: baxdrostat (BAXFENDY, aldosterone synthase inhibitor, FDA-approved May 2026, 1 mg or 2 mg once daily), aprocitentan (TRYVIO, endothelin receptor antagonist, 12.5 mg once daily, boxed warning for embryo-fetal toxicity), spironolactone (ALDACTONE, labeled “as add-on therapy for the treatment of hypertension”), and eplerenone (INSPRA, 50 mg once daily, up to 50 mg twice daily). Two renal denervation systems received FDA premarket approval in November 2023 as “adjunctive treatment” when lifestyle modifications and antihypertensive medications do not control blood pressure.
  • Placebo-adjusted change in office systolic blood pressure in the pivotal trials: baxdrostat -9.8 mmHg (2 mg) and -8.7 mmHg (1 mg) at week 12 in BaxHTN; aprocitentan 12.5 mg -3.8 mmHg at week 4; lorundrostat 50 mg -9.1 mm Hg at week 6 in Launch-HTN. The trials differ in time point, measurement method, and background therapy, and no head-to-head trial of lorundrostat against another add-on drug was identified.
  • Indirect comparisons: in a drug-level network meta-analysis of 10 trials (2,865 participants) with resistant hypertension, the mean differences in office systolic blood pressure versus placebo were -14.08 mmHg (amiloride), -10.78 mmHg (spironolactone), -9.09 mmHg (baxdrostat), -8.14 mmHg (eplerenone), and -6.80 mmHg (lorundrostat). ICER rated the evidence “insufficient” (I) for baxdrostat versus lorundrostat in all three of its populations, “Promising but Inconclusive” (P/I) for either drug versus spironolactone, eplerenone, or amiloride in Populations 1 and 2, and “comparable or inferior” (C-) versus amlodipine in Population 3.
  • Hyperkalemia in ICER's comparison table: baxdrostat 6.6% (1 mg) and 10.2% (2 mg) against 2.5% with placebo; lorundrostat 50 mg 2.5% against 0.3% with placebo.
Baxdrostat (BAXFENDY): prescribing information
FieldQuoted label text
Indication“BAXFENDY is an aldosterone synthase inhibitor indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.”
Recommended dosage“The recommended dosage of BAXFENDY is 2 mg orally once daily.”
Dosage at increased risk of hyperkalemia or hyponatremia“For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily”
Strengths“Tablets: 1 mg and 2 mg”
Contraindications“None.”
Warnings and precautions“Hyperkalemia: Assess serum potassium before initiation and periodically thereafter.”
Warnings and precautions“Hyponatremia: Assess serum sodium before initiation and periodically thereafter.”
Most common adverse reaction“The most common adverse reaction (more frequent than placebo and ≥ 5% in BAXFENDY-treated patients) was hyperkalemia.”
Drug interactions“Strong and moderate CYP3A inducers: Monitor the therapeutic effect of BAXFENDY more frequently during concomitant use.”
Renal impairment“Safety and effectiveness of BAXFENDY initiated in patients with eGFR < 45 mL/min/1.73 m2 have not been established”
Elimination half-life“The mean effective half-life of baxdrostat was approximately 26 hours (range 23 to 32 hours).”
Cardiovascular outcomes“There are no controlled trials demonstrating risk reduction of these events with BAXFENDY.”
Aprocitentan (TRYVIO, Idorsia): prescribing information
Zilebesiran (Alnylam and Roche): investigational subcutaneous siRNA against angiotensinogen
ICER network meta-analysis, Population 3 (not at goal on two drugs, third first-line agent not yet tried): systolic blood pressure versus placebo
Add-on drugMean difference versus placebo, mm Hg (95% credible interval)
Baxdrostat“-10.1 (-16.6, -3.9)”
Lorundrostat“-8.6 (-12.4, -4.8)”
Amlodipine“-8.3 (-10.7, -6.2)”